Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-11 of 11

Sort by

Sort Order Select

Journal Articles

CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer

Jesse Boumelha, Andrea de Castro, Nourdine Bah, Hongui Cha, Sophie de Carné Trécesson, Sareena Rana, Mona Tomaschko, Panayiotis Anastasiou, Edurne Mugarza, Christopher Moore, Robert Goldstone, Phil East, Kevin Litchfield, Se-Hoon Lee, Miriam Molina-Arcas, Julian Downward

Cancer Res (2024) 84 (14): 2231–2246.

https://doi.org/10.1158/0008-5472.CAN-23-2627

Published: 15 July 2024

View articletitled, CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer

Includes: Supplementary data

Journal Articles

Abstract 1214: Investigating therapeutic strategies to promote immune rejection of KRAS^G12C inhibitor-resistant subpopulations in lung cancer

Mona Tomaschko, Christopher Moore, Claire E. Pillsbury, Kangbo Ng, Sophie de Carne, Sareena Rana, Andrea de Castro, Panayiotis Anastasiou, Miriam Molina-Arcas, Julian Downward

Cancer Res (2024) 84 (6_Supplement): 1214.

https://doi.org/10.1158/1538-7445.AM2024-1214

Published: 22 March 2024

View articletitled, Abstract 1214: Investigating therapeutic strategies to promote immune rejection of KRASG12C inhibitor-resistant subpopulations in lung cancer

Journal Articles

Abstract 4155: The RAF/MEK clamp avutometinib (VS-6766) induces an immunogenic tumor microenvironment and potentiates the efficacy of anti-PD-1

Silvia Coma, Miriam Molina Arcas, Julian Downward, Jonathan A. Pachter

Cancer Res (2023) 83 (7_Supplement): 4155.

https://doi.org/10.1158/1538-7445.AM2023-4155

Published: 04 April 2023

View articletitled, Abstract 4155: The RAF/MEK clamp avutometinib (VS-6766) induces an immunogenic tumor microenvironment and potentiates the efficacy of anti-PD-1

Journal Articles

Abstract 5733: Combining KRAS^G12C(ON) inhibition with SHP2 and immune checkpoint blockade to enhance anti-tumor immunity and overcome development of resistance in lung cancer

Panayiotis Anastasiou, Mona Tomaschko, Jesse Boumelha, Sareena Rana, Christopher Moore, Miriam Molina-Arcas, Julian Downward

Cancer Res (2023) 83 (7_Supplement): 5733.

https://doi.org/10.1158/1538-7445.AM2023-5733

Published: 04 April 2023

View articletitled, Abstract 5733: Combining KRASG12C(ON) inhibition with SHP2 and immune checkpoint blockade to enhance anti-tumor immunity and overcome development of resistance in lung cancer

Journal Articles

An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations

Cancer Res (2022) 82 (19): 3435–3448.

https://doi.org/10.1158/0008-5472.CAN-22-0325

Published: 04 October 2022

View articletitled, An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations

Includes: Supplementary data

Journal Articles

Abstract 1352: In vivo CRISPR screening identifies mediators of immune evasion in KRAS-mutant lung cancer

Jesse Boumelha, Pablo Romero-Clavijo, Sophie de Carné, Miriam Molina-Arcas, Julian Downward

Cancer Res (2022) 82 (12_Supplement): 1352.

https://doi.org/10.1158/1538-7445.AM2022-1352

Published: 15 June 2022

View articletitled, Abstract 1352: In vivo CRISPR screening identifies mediators of immune evasion in KRAS-mutant lung cancer

Journal Articles

Abstract 4029: Combination of KRAS^G12C(ON) and SHP2 inhibitors overcomes adaptive resistance and enhances anti-tumor immunity

Panayiotis Anastasiou, Edurne Mugarza, Jesse Boumelha, Sareena Rana, Christopher Moore, Miriam Molina-Arcas, Julian Downward

Cancer Res (2022) 82 (12_Supplement): 4029.

https://doi.org/10.1158/1538-7445.AM2022-4029

Published: 15 June 2022

View articletitled, Abstract 4029: Combination of KRASG12C(ON) and SHP2 inhibitors overcomes adaptive resistance and enhances anti-tumor immunity

Journal Articles

Abstract 1820: Uncovering mechanisms of immune evasion in a novel immunogenic model of KRAS-mutant lung cancer

Jesse Boumelha, Sophie de Carné, Edurne Mugarza, Pablo Romero-Clavijo, Miriam Molina-Arcas, Julian Downward

Cancer Res (2021) 81 (13_Supplement): 1820.

https://doi.org/10.1158/1538-7445.AM2021-1820

Published: 01 July 2021

View articletitled, Abstract 1820: Uncovering mechanisms of immune evasion in a novel immunogenic model of KRAS-mutant lung cancer

Journal Articles

Abstract 2987: Identification of new combination therapies for lung tumors harboring KRAS mutations

Miriam Molina-Arcas, Christopher Moore, Sareena Rana, Febe van Maldegem, Stuart Horswell, David Hancock, Julian Downward

Cancer Res (2018) 78 (13_Supplement): 2987.

https://doi.org/10.1158/1538-7445.AM2018-2987

Published: 01 July 2018

View articletitled, Abstract 2987: Identification of new combination therapies for lung tumors harboring KRAS mutations

Journal Articles

Abstract 4163: Determination of synthetic lethal interactions in KRAS oncogene dependent cancer cells reveals novel therapeutic targeting strategies

Miriam Molina-Arcas, David Hancock, Michael Steckel, Julian Downward

Cancer Res (2012) 72 (8_Supplement): 4163.

https://doi.org/10.1158/1538-7445.AM2012-4163

Published: 15 April 2012

View articletitled, Abstract 4163: Determination of synthetic lethal interactions in KRAS oncogene dependent cancer cells reveals novel therapeutic targeting strategies

Journal Articles

Human equilibrative nucleoside transporter 1 (hENT1) expression correlates with gemcitabine uptake and cytotoxicity in mantle cell lymphoma (MCL)

Silvia Marce, Miriam Molina-Arcas, Neus Villamor, F. Javier Casado, Elias Campo, Marçal Pastor-Anglada, Dolors Colomer

Cancer Res (2006) 66 (8_Supplement): 555.

Published: 15 April 2006

View articletitled, Human equilibrative nucleoside transporter 1 (hENT1) expression correlates with gemcitabine uptake and cytotoxicity in mantle cell lymphoma (MCL)

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer

Abstract 1214: Investigating therapeutic strategies to promote immune rejection of KRAS^G12C inhibitor-resistant subpopulations in lung cancer

Abstract 4155: The RAF/MEK clamp avutometinib (VS-6766) induces an immunogenic tumor microenvironment and potentiates the efficacy of anti-PD-1

Abstract 5733: Combining KRAS^G12C(ON) inhibition with SHP2 and immune checkpoint blockade to enhance anti-tumor immunity and overcome development of resistance in lung cancer

An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations

Abstract 1352: In vivo CRISPR screening identifies mediators of immune evasion in KRAS-mutant lung cancer

Abstract 4029: Combination of KRAS^G12C(ON) and SHP2 inhibitors overcomes adaptive resistance and enhances anti-tumor immunity

Abstract 1820: Uncovering mechanisms of immune evasion in a novel immunogenic model of KRAS-mutant lung cancer

Abstract 2987: Identification of new combination therapies for lung tumors harboring KRAS mutations

Abstract 4163: Determination of synthetic lethal interactions in KRAS oncogene dependent cancer cells reveals novel therapeutic targeting strategies

Human equilibrative nucleoside transporter 1 (hENT1) expression correlates with gemcitabine uptake and cytotoxicity in mantle cell lymphoma (MCL)

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only